Welcome to our dedicated page for Baudax Bio news (Ticker: BXRX), a resource for investors and traders seeking the latest updates and insights on Baudax Bio stock.
Baudax Bio, Inc. (NASDAQ: BXRX) is a specialized pharmaceutical company focused on developing and commercializing innovative products designed to meet the needs of hospital and acute care settings. The company's lead product candidate is an intravenous form of meloxicam, a non-opioid analgesic that has completed Phase III clinical trials for the management of moderate to severe pain. Current research includes Phase IIIB clinical trials aiming to assess opioid consumption, pain intensity, and the length of hospital stay in colorectal and orthopedic surgery patients. These trials also evaluate various pharmacoeconomic parameters.
Beyond meloxicam, Baudax Bio is advancing a pipeline of early-stage product candidates including RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) in Phase I clinical trials, and RP2000, an ultra-short-acting NMBA currently in pre-clinical trials. The company is also developing a reversal agent for these NMBAs and DEX-IN, a proprietary intranasal formulation of dexmedetomidine.
Recently, Baudax Bio announced that the U.S. FDA has granted orphan drug designation to its lead clinical candidate TI-168 for the treatment of Hemophilia A with inhibitors. TI-168 is a next-generation Treg therapy designed to address Hemophilia A patients with FVIII inhibitors effectively.
Founded in 2019 and based in Malvern, Pennsylvania, Baudax Bio continues to push forward with its mission to develop meaningful therapeutic solutions for acute care settings, drawing on robust clinical research and innovative therapeutic approaches.
Baudax Bio (NASDAQ: BXRX) announced a Special Meeting of shareholders scheduled for July 13, 2021, to vote on increasing the authorized shares of common stock from 100 million to 190 million. The meeting will be held virtually at 9:00 a.m. Eastern Time. Leading proxy advisory firms, Glass Lewis and Institutional Shareholder Services, recommend shareholders vote 'for' the increase. This proposal aims to facilitate future capital-raising efforts necessary for the company's growth and product development.
Baudax Bio (NASDAQ:BXRX) announced that its President and CEO, Gerri Henwood, will participate in a virtual fireside chat at the JMP Securities Life Sciences Conference on June 17, 2021, at 4:00 p.m. ET. A live webcast will be available on the company’s investors page, with a replay accessible for 30 days post-event. Baudax Bio focuses on acute care pharmaceutical innovations, including its first product, ANJESO, launched in mid-2020, which is a unique 24-hour intravenous NSAID for managing moderate to severe pain. More details are on the company website.
Baudax Bio (NASDAQ:BXRX) announced that its product ANJESO® (meloxicam) injection achieved approval at over 100 U.S. formularies within a year of its launch. This milestone is expected to enhance its usage in hospitals and ambulatory care centers. CEO Gerri Henwood reported growth in new accounts, sales, and reorder rates, indicating positive market reception. ANJESO offers a non-opioid alternative for managing moderate to severe pain, reducing the risks associated with traditional opioids. The company remains focused on successful commercialization as hospital procedures normalize.
On May 31, 2021, Baudax Bio (NASDAQ:BXRX) announced a registered direct offering to institutional investors for the sale of 14,028,520 shares and warrants at $0.85 per share. The warrants, exercisable at $0.90, will expire on December 1, 2026. The offering is expected to generate approximately $11.9 million in gross proceeds, potentially increasing to $24.5 million if all warrants are exercised. Funds will be allocated for commercialization of ANJESO®, pipeline development, and general corporate purposes. The offering's closing date is expected around June 1, 2021.
Baudax Bio, Inc. (NASDAQ:BXRX) has decided to withdraw Proposal 3 from its Definitive Proxy Statement concerning the increase of common stock shares. This cancellation halts the reconvening of the annual shareholder meeting initially set for June 3, 2021, focused solely on this proposal. Other agenda items were voted on during the April 7, 2021 meeting. Baudax Bio, known for its innovative acute care products like ANJESO, aims to enhance its product pipeline as it navigates future opportunities.
MALVERN, Pa., May 27, 2021 – Baudax Bio (NASDAQ:BXRX) announced that CEO Gerri Henwood will present at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 2:00 p.m. ET. The presentation will be available via live webcast on the company's website and will be accessible for replay for 30 days post-event. Baudax Bio focuses on innovative products for acute care, highlighting its first commercial product, ANJESO®, an IV NSAID approved for moderate to severe pain management, which has undergone extensive clinical trials. For more details, visit Baudax Bio.
Baudax Bio announced positive results from its Phase IIIb study of ANJESO (meloxicam) showing significant benefits for patients undergoing colorectal surgery. The study demonstrated that ANJESO reduced postoperative opioid use by 35% and decreased hospital length of stay by an average of 28 hours compared to placebo. More than 92% of patients reported satisfaction with the treatment, highlighting its efficacy and safety. With a focus on lowering opioid consumption, ANJESO aligns with enhanced recovery after surgery (ERAS) protocols, marking an important advancement in pain management.
Baudax Bio (NASDAQ:BXRX) has adjourned its 2021 Annual Meeting of Shareholders concerning Proposal 3, which aims to amend the Articles of Incorporation to increase authorized shares from 100 million to 190 million. The adjournment provides shareholders additional time to vote, with the resumption scheduled for June 3, 2021. Shareholders eligible to vote remain as of March 1, 2021, and previously submitted proxies will remain valid. Baudax Bio focuses on acute care pharmaceuticals, including its first product, ANJESO, a 24-hour IV NSAID.
Baudax Bio reported Q1 2021 financial results, showcasing a 40% increase in ANJESO unit sales compared to Q4 2020, with a 30% rise in average sales per account. The company executed agreements with top distributors, achieving 90 formulary wins, a 30% increase. Despite ongoing COVID-19 challenges impacting elective procedures, ANJESO usage expanded significantly. Financially, Baudax reported a net loss of $16.9 million or $(0.27) per share, an improvement from a $40.3 million loss in Q1 2020. Cash reserves stood at $38.2 million as of March 31, 2021.
Baudax Bio (BXRX) has scheduled a conference call to discuss its first quarter 2021 financial results on May 5, 2021, at 8:00 a.m. ET. Investors can access the call by dialing (866) 220-5595. The company continues to focus on its innovative product, ANJESO®, which is the first 24-hour IV COX-2 preferential NSAID for pain management. ANJESO has completed three Phase III clinical trials and is set to impact the acute care market.
FAQ
What is the market cap of Baudax Bio (BXRX)?
What is the primary focus of Baudax Bio, Inc.?
What is Baudax Bio's lead product candidate?
What other products are in Baudax Bio's pipeline?
What recent regulatory milestone has Baudax Bio achieved?
Where is Baudax Bio headquartered?
When was Baudax Bio incorporated?
What is the status of meloxicam's clinical trials?
What is TI-168?
Who can I contact for investor relations information?
Are there any other clinical trials Baudax Bio is involved in?
